MedTrace Logo

Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients

NCT03738683 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-11-21

No results posted yet for this study

Summary

Optimal understanding of piperacillin-tazobactam pharmacokinetics in critically ill patients is lacking resulting in large variation of achieved exposure and possible inadequate therapy. The investigators hypothesize that drug dosing based on CKD-EPIcr-cys provides a useful method to individualize and optimize therapy for piperacillin-tazobactam and eventually improve outcome.

In a multi-centre, observational, open-label study the investigators aim to define PK of free drug concentrations of both piperacillin and tazobactam in ICU patients and define a PK model for estimation of renal function that most accurately predicts piperacillin and tazobactam clearance.

Conditions

Interventions

DRUG

Piperacillin/tazobactam

Dose according to summary of product characteristics (SPC) or local protocols

Sponsors & Collaborators

  • UMC Utrecht

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2019-09-01
Completion
2019-10-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03738683 on ClinicalTrials.gov